TY - JOUR
T1 - Physical Effects of Short-Term Recombinant Human Growth Hormone Administration in Abstinent Steroid Dependency
AU - Graham, Michael
AU - Thomas, Nancy
AU - Davies, Bruce
AU - Baker, Julien S.
AU - Evans, Peter
AU - Kicman, Andrew
AU - Cowan, David
AU - Hullin, David A.
PY - 2008/3/17
Y1 - 2008/3/17
N2 - Abstract Background/Aims: Recombinant human growth hormone (rhGH) as opposed to cadaver pituitary GH is misused for physical improvement. Six days' rhGH administration, in abstinent anabolic-androgenic steroid dependents, was compared with controls. Method: Male subjects (n = 48) were randomly divided into two groups: (1): control group (C), n = 24, mean ± SD, age 32 ± 11 years, height 1.8 ± 0.06 m; (2): rhGH-using group (0.058 IU·kg-1·day-1) (GH), n = 24, mean ± SD, age 32 ± 9 years, height 1.8 ± 0.07 m. Physiological measurements included anthropometry, strength, power and peak oxygen uptake (VO2 peak). Biochemical measurements included haemoglobin, packed cell volume, glucose, sodium, potassium, urea, creatinine, total protein, albumin, thyroid function, testosterone, prolactin, cortisol, GH and insulin-like growth factor-I (IGF-I). Results: Strength, peak power output and IGF-I significantly increased and total protein, albumin and free tetra-iodothyronine significantly decreased compared to controls (p andlt; 0.05) and within the GH group (p andlt; 0.017). Fat-free mass index and VO2 peak significantly increased, while body fat and thyroid-stimulating hormone significantly decreased within the GH group (p andlt; 0.017). Conclusions: Short-term rhGH increased strength and power. Of therapeutic value is the possibility that muscle bulk and strength could be increased in patients with muscle-wasting conditions.
AB - Abstract Background/Aims: Recombinant human growth hormone (rhGH) as opposed to cadaver pituitary GH is misused for physical improvement. Six days' rhGH administration, in abstinent anabolic-androgenic steroid dependents, was compared with controls. Method: Male subjects (n = 48) were randomly divided into two groups: (1): control group (C), n = 24, mean ± SD, age 32 ± 11 years, height 1.8 ± 0.06 m; (2): rhGH-using group (0.058 IU·kg-1·day-1) (GH), n = 24, mean ± SD, age 32 ± 9 years, height 1.8 ± 0.07 m. Physiological measurements included anthropometry, strength, power and peak oxygen uptake (VO2 peak). Biochemical measurements included haemoglobin, packed cell volume, glucose, sodium, potassium, urea, creatinine, total protein, albumin, thyroid function, testosterone, prolactin, cortisol, GH and insulin-like growth factor-I (IGF-I). Results: Strength, peak power output and IGF-I significantly increased and total protein, albumin and free tetra-iodothyronine significantly decreased compared to controls (p andlt; 0.05) and within the GH group (p andlt; 0.017). Fat-free mass index and VO2 peak significantly increased, while body fat and thyroid-stimulating hormone significantly decreased within the GH group (p andlt; 0.017). Conclusions: Short-term rhGH increased strength and power. Of therapeutic value is the possibility that muscle bulk and strength could be increased in patients with muscle-wasting conditions.
KW - insulin-like growth factor-i
KW - physical stress
KW - recombinant human growth hormone
KW - strength
U2 - 10.1159/000117390
DO - 10.1159/000117390
M3 - Article
C2 - 18504393
SN - 1663-2826
VL - 69
SP - 343
EP - 354
JO - Hormone Research in Pediatrics
JF - Hormone Research in Pediatrics
IS - 6
ER -